Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting (AGM) of the company will be held on 18 September 2024.Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals declined 28.74% to Rs 5.33 crore in the quarter ended June 2024 as against Rs 7.48 crore during the previous quarter ended June 2023. Sales rose 2.14% to Rs 61.44 crore in the quarter ended June 2024 as against Rs 60.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales61.4460.15 2 OPM %16.6814.35 - PBDT11.4710.48 9 PBT10.4010.09 3 NP5.337.48 -29 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2024Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals completed the acquisition of India & Bhutan business of Yash Pharma Laboratories along with the brands and associated trademark. The acquired business shall be consolidated with the Company`s financials with effect from 01 June 2024.Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 20 May 2024, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 100%) , subject to the approval of the shareholders.Powered by Capital Market - Live News